Kymera Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
BVF Partners and affiliated entities sold 1,630,658 shares of Kymera Therapeutics at $106.50 per share on June 26, 2026.
NASDAQ
BVF Partners and affiliated entities have updated their beneficial ownership in Kymera Therapeutics, Inc. to 8.5% following an increase in the issuer's outstanding shares.
NASDAQ
Baker Bros. Advisors LP and its affiliates increased their beneficial ownership in Kymera Therapeutics, Inc. to 10.9% by participating in a recent public offering.
NASDAQ
Baker Bros. Advisors and its affiliated funds have increased their beneficial ownership in Kymera Therapeutics, Inc. to 9.5% of outstanding common stock after participating in a recent public offering of shares and prefunded warrants.